Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis

Company Overview

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development, commercialization and marketing of prescription therapies addressing women’s health and related endocrine conditions. Headquartered in Mississauga, Ontario, with commercial operations in Princeton, New Jersey, the company leverages licensing and co-promotion agreements to bring novel hormone therapies to market.

The company’s commercial portfolio includes CombiPatch, a combined estradiol/testosterone transdermal system indicated for hormone replacement therapy in post-menopausal women, and IMVEXXY, a low-dose estradiol vaginal insert for the treatment of dyspareunia associated with menopausal vulvar and vaginal atrophy. Both products are marketed under license from Endoceutics, Inc., and are sold in the United States and Canada through Acerus’s dedicated sales teams and strategic partners.

Beyond its marketed products, Acerus maintains a clinical development pipeline aimed at unmet needs in women’s sexual health and men’s hypogonadism. Lead programs include an injectable testosterone therapy for female sexual dysfunction and a transdermal gel formulation targeting male testosterone deficiency. The company also explores new delivery technologies and formulations to enhance the safety and convenience of hormone therapies.

Acerus is led by President and Chief Executive Officer Jonathan G. Barrett, whose background in pharmaceutical strategy and business development supports the company’s growth initiatives. Through its North American footprint and collaborative agreements, Acerus seeks to expand patient access to specialized endocrine treatments.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.22 to $8.16
• Volume: N/A
• Average Volume: 1,500 shs
• Market Capitalization: $1.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASPCF Stock Analysis - Frequently Asked Questions

How have ASPCF shares performed this year?

Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2025. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22.

When did Acerus Pharmaceuticals' stock split?

Shares of Acerus Pharmaceuticals reverse split before market open on Friday, April 29th 2022.The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ASPCF
• CIK: N/A
• Web: www.aceruspharma.com
• Phone: (416) 679-0771
• Fax: 905-569-1809
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.82 million
• Net Margins: -924.33%
• Pretax Margin: -924.33%
• Return on Equity: N/A
• Return on Assets: -74.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.67
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $2.12 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.38) per share
• Price / Book: -0.07

Miscellaneous

• Outstanding Shares: 7,708,000
• Free Float: N/A
• Market Cap: $1.70 million
• Optionable: Not Optionable
• Beta: 0.69